Clinical trials: 5-FU, completed
Biliary Tract Cancer
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin for…
- Trial name
- NCT03785873
- Testing
- Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Actinic Keratosis
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.
- Trial name
- NCT02616601
- Testing
- Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
- Where
- 17 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol…
- Trial name
- ATOM (NCT01836653)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- EPS Corporation
Stage III Esophageal Squamous Cell Carcinoma
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
The purpose of this study is to determined the best scheme in paclitaxel and cisplatin，paclitaxel and fluorouracil，paclitaxel and carboplatin concurrent with radiotherapy for patients with local advanced esophageal Squamous Cell…
- Trial name
- NCT02459457
- Testing
- Paclitaxel and Cisplatin, Paclitaxel and Fluorouracil, Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Fudan University
Lumbar Disc Herniation
Bladder Meridian Gua Sha for Lumbar Disc Herniation: Efficacy and CRP Regulation Via Cutaneous-Meridian-Visceral Axis in Shen Period
Based on the "Cutaneous Region-Meridian-Visceral" axis theory, in this study, we investigated clinical efficacy of the Gua Sha intervention on the Bladder Meridian during the Shen Period (3:00-5:00 p.m.) for lumbar disc…
- Trial name
- CRP (NCT07754422)
- Testing
- Control group（standard treatment and care）, Observation group（standard treatment supplemented with Gua Sha）
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Bile Duct Cancer
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
Bile duct tumours are rare. They are the 6th most common type of digestive cancer. Their therapeutic management is complex and must be multidisciplinary in nature.
- Trial name
- AMEBICA (NCT02591030)
- Testing
- GEMCIS, mFolfirinox
- Where
- 42 sites in France
- Volunteers
- 191 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Squamous Cell Carcinoma of the Head and Neck
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer.
- Trial name
- NCT00513383
- Testing
- Panitumumab, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Recurrent Colon Cancer, Recurrent Rectal Cancer
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00138177
- Testing
- oxaliplatin, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer
The purpose of this study is to explore whether adjuvant chemotherapy regimens guided by organoid drug sensitivity test can improve the outcomes of pancreatic cancer.
- Trial name
- NCT04931394
- Testing
- Adjuvant chemotherapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Changhai Hospital
Metastatic Colorectal Cancer
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
This study is being done to determine the maximum dose of a certain chemotherapy drug (irinotecan) that can be tolerated as part of a combination of drugs.
- Trial name
- NCT01183494
- Testing
- FOLFIRI, Avastin, Irinotecan
- Where
- 2 sites in United States, Italy
- Volunteers
- 17 people
- Sponsor
- University of Chicago
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
The aim of this study was to evaluate the efficacy and safety of continuing cetuximab combined with chemotherapy after first-line progression in wild-type KRAS,NRAS and BRAF colorectal cancer.
- Trial name
- NCT04718038
- Testing
- Cetuximab combind mFOLFOX6/FOLFIRI
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Henan Cancer Hospital
Head and Neck Cancer
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
Two new cancer treatment drugs called targeted therapies will be added to standard treatment for head and neck cancer to see if an improvement can be made in the effectiveness of treatment for this type of cancer.
- Trial name
- NCT00392704
- Testing
- Bevacizumab, Erlotinib, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Adenocarcinoma
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or…
- Trial name
- AVAGAST (NCT00548548)
- Testing
- Bevacizumab, Capecitabine, Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 774 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer, Liver Metastases
FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
This is an open label single arm prospective multicenter Phase II study in around 20 patients. The primary objective of this study is to evaluate whether the addition of sunitinib to FOLFIRI results in a significant reduction of…
- Trial name
- NCT00806663
- Testing
- sunitinib added to FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Colorectal Cancer, Metastatic Cancer
Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Radiofrequency ablation may be able to shrink or destroy cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004142
- Testing
- Floxuridine, Fluorouracil (5-FU), Conventional surgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies, unmet medical needs and limited treatment options still exist for patients with metastatic PDAC…
- Trial name
- NCT06378580
- Testing
- Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Luo Cong
Neoplasms, Advanced
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
This is a Phase I dose escalation trial with escalating doses of Valproic acid and one dose escalation step of epirubicin. VPA will be escalated starting at a dose that is recommended for use as an anti-convulsant or to treat…
- Trial name
- NCT00246103
- Testing
- Valproic acid, Epirubicin, 5-fluorouracil
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Head and Neck Cancer
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT00122460
- Testing
- Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU), Platinum (Cisplatin or Carboplatin) + 5-FU
- Where
- 70 sites in Austria, Belgium and 15 more
- Volunteers
- 442 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
The scope of this study is to evaluate the efficacy of the addition of atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with metastatic colorectal cancer in terms of Progression Free Survival.
- Trial name
- AtezoTRIBE (NCT03721653)
- Testing
- Bevacizumab, Irinotecan, Oxaliplatin
- Where
- Italy
- Volunteers
- 218 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.